

USA and EU regulatory submissions for veterinary medicines

Karolina Bate

Cyton Biosciences Limited, UK

The USA and the EU are the 2 major animal health markets in the world.

A combined USA/EU drug development approach allows pharmaceutical companies to co-ordinate resources, shorten development times, promote financial efficiency and ultimately expand revenue.

However, a combined approach faces many challenges, as both the USA and EU have significantly different regulatory frameworks, timeframes and requirements.

In such a highly regulated industry, knowledge of both USA and EU regulatory requirements, procedure, policy and standards is crucial in order to conduct joint USA/EU programs of development, prepare dossiers for submission and obtain marketing authorizations in both territories.

This presentation will describe the similarities and differences between the USA and EU requirements for obtaining a marketing authorization for a veterinary medicinal Product.

Biography

Karolina Bate has a Bachelor's Degree in Pharmacology and a Ph.D. in Immunology from the University of Wales, Cardiff. She joined Cyton Biosciences Ltd in 2007 and currently holds the position of Projects Director. Cyton Biosciences Ltd is a regulatory consultancy based in the UK, which is part of the global Knoell Group.

KBate@cyton.com